Unknown statusInterventionalPhase 2Updated Jun 22, 2017
A Phase II Study to Determine the Safety and Efficacy of Second-line Treatment With Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the Second... | NCT01926769 | Trialant
TerminatedInterventionalPhase 2Updated May 15, 2018
A Phase II Study to Determine the Safety and Efficacy of Second-line Treatment With Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the Second Line Threatment of Advanced Colorectal Cancer
ClinicalTrials.gov ID
NCT01926769
Lead Sponsor
Gachon University Gil Medical CenterOTHER
Overall Status
Terminated
Study Type
Interventional
Phase
Phase 2
Enrollment
2Actual
Last Update Posted
May 15, 2018Actual
Start Date
Feb 2012Actual
Primary Completion Date
Dec 2014Actual
Completion Date
Dec 2014Actual
Brief Summary
To determine the safety and efficacy of second-line treatment with Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the second line treatment of advanced colorectal cancer
Previously Treated Advanced Colorectal Cancer
Metformin
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age over 18
histologically confirmted advanced colorectal cancer
ECOG PS 0-2
expected life span more than 3months
normal bone marrow, liver, renal function
Exclusion Criteria:
5-FU, oxaliplatin, irinotecan or Metformin Allergic history